OpenURL Connection Search

Select item for more details and to access through your institution.

CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE.
Published in:
Hematological Oncology, 2019, v. 37, p. 269, doi. 10.1002/hon.80_2630
By:
- Novo, M.;
- Nowakowski, G.S.;
- Micallef, I.N.;
- Ristow, K.;
- Habermann, T.M.;
- Johnston, P.B.
Publication type:
Article
PET‐CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META‐ANALYSIS.
Published in:
Hematological Oncology, 2019, v. 37, p. 250, doi. 10.1002/hon.59_2630
By:
- Berry, D.A.;
- Broglio, K.R.;
- Ward, C.;
- Sahin, D.;
- Nielsen, T.;
- Mattiello, F.;
- McGlothlin, A.E.;
- Wendelberger, B.A.;
- Foster, M.;
- Nowakowski, G.S.;
- Kostakoglu, L.
Publication type:
Article
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
By:
- Nowakowski, G.S.;
- Hong, F.;
- Scott, D.W.;
- Macon, R.;
- King, R.L.;
- Habermann, T.M.;
- Wagner‐Johnston, N.;
- Casulo, C.;
- Wade, J.L.;
- Nagargoje, G.G.;
- Reynolds, C.M.;
- Cohen, J.B.;
- Khan, N.;
- Amengual, J.;
- Richards, K.L.;
- Little, R.F.;
- Leonard, J.P.;
- Friedberg, J.W.;
- Kostakoglu, L.;
- Kahl, B.S.
Publication type:
Article
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY.
Published in:
Hematological Oncology, 2019, v. 37, p. 231, doi. 10.1002/hon.44_2630
By:
- Maurer, M.J.;
- Jakopsen, L.H.;
- Habermann, T.M.;
- Nowakowski, G.S.;
- Ansell, S.M.;
- Thompson, C.A.;
- Brown, P.D.;
- Jørgensen, J.M.;
- Frederiksen, H.;
- Syrbu, S.;
- Feldman, A.L.;
- Novak, A.J.;
- Rimsza, L.M.;
- Cerhan, J.R.;
- El‐Galaly, T.C.;
- Link, B.K.
Publication type:
Article
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY).
Published in:
Hematological Oncology, 2019, v. 37, p. 70, doi. 10.1002/hon.37_2629
By:
- Zhu, J.;
- Song, Y.;
- Smith, S.D.;
- O'Connor, O.A.;
- Luo, W.;
- Shazer, R.L.;
- Zhang, L.;
- Han, I.;
- Jivani, M.A.;
- Liu, Y.;
- Nowakowski, G.S.
Publication type:
Article
PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION.
Published in:
Hematological Oncology, 2019, v. 37, p. 48, doi. 10.1002/hon.18_2629
By:
- Novo, M.;
- Nowakowski, G.S.;
- Habermann, T.M.;
- Witzig, T.E.;
- Micallef, I.N.;
- Johnston, P.B.;
- Inwards, D.J.;
- Ristow, K.;
- Young, J.R.;
- Ansell, S.M.
Publication type:
Article
CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE.
Published in:
Hematological Oncology, 2019, v. 37, p. 269, doi. 10.1002/hon.80_2630
By:
- Novo, M.;
- Nowakowski, G.S.;
- Micallef, I.N.;
- Ristow, K.;
- Habermann, T.M.;
- Johnston, P.B.
Publication type:
Article
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
By:
- Nowakowski, G.S.;
- Hong, F.;
- Scott, D.W.;
- Macon, R.;
- King, R.L.;
- Habermann, T.M.;
- Wagner‐Johnston, N.;
- Casulo, C.;
- Wade, J.L.;
- Nagargoje, G.G.;
- Reynolds, C.M.;
- Cohen, J.B.;
- Khan, N.;
- Amengual, J.;
- Richards, K.L.;
- Little, R.F.;
- Leonard, J.P.;
- Friedberg, J.W.;
- Kostakoglu, L.;
- Kahl, B.S.
Publication type:
Article
PET‐CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META‐ANALYSIS.
Published in:
Hematological Oncology, 2019, v. 37, p. 250, doi. 10.1002/hon.59_2630
By:
- Berry, D.A.;
- Broglio, K.R.;
- Ward, C.;
- Sahin, D.;
- Nielsen, T.;
- Mattiello, F.;
- McGlothlin, A.E.;
- Wendelberger, B.A.;
- Foster, M.;
- Nowakowski, G.S.;
- Kostakoglu, L.
Publication type:
Article
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY.
Published in:
Hematological Oncology, 2019, v. 37, p. 231, doi. 10.1002/hon.44_2630
By:
- Maurer, M.J.;
- Jakopsen, L.H.;
- Habermann, T.M.;
- Nowakowski, G.S.;
- Ansell, S.M.;
- Thompson, C.A.;
- Brown, P.D.;
- Jørgensen, J.M.;
- Frederiksen, H.;
- Syrbu, S.;
- Feldman, A.L.;
- Novak, A.J.;
- Rimsza, L.M.;
- Cerhan, J.R.;
- El‐Galaly, T.C.;
- Link, B.K.
Publication type:
Article
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY).
Published in:
Hematological Oncology, 2019, v. 37, p. 70, doi. 10.1002/hon.37_2629
By:
- Zhu, J.;
- Song, Y.;
- Smith, S.D.;
- O'Connor, O.A.;
- Luo, W.;
- Shazer, R.L.;
- Zhang, L.;
- Han, I.;
- Jivani, M.A.;
- Liu, Y.;
- Nowakowski, G.S.
Publication type:
Article
PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION.
Published in:
Hematological Oncology, 2019, v. 37, p. 48, doi. 10.1002/hon.18_2629
By:
- Novo, M.;
- Nowakowski, G.S.;
- Habermann, T.M.;
- Witzig, T.E.;
- Micallef, I.N.;
- Johnston, P.B.;
- Inwards, D.J.;
- Ristow, K.;
- Young, J.R.;
- Ansell, S.M.
Publication type:
Article
ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING.
Published in:
Hematological Oncology, 2017, v. 35, p. 419, doi. 10.1002/hon.2440
By:
- Chiappella, A.;
- Witzig, T.E.;
- Vitolo, U.;
- Gascoyne, R.;
- Russo, J.;
- Amoroso, B.;
- Hudak, K.;
- Ogunkanmi, A.;
- Xu, Y.;
- Ruiz, W.;
- Singh, S.;
- Nowakowski, G.S.
Publication type:
Article
GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA.
Published in:
Hematological Oncology, 2017, v. 35, p. 55, doi. 10.1002/hon.2437_40
By:
- Fama, A.;
- Allmer, C.;
- Link, B.K.;
- Xiang, J.;
- Klinzman, D.;
- Feldman, A.J.;
- Nowakowski, G.S.;
- Liebow, M.;
- Larson, M.C.;
- Slager, S.L.;
- Call, T.G.;
- Habermann, T.M.;
- Cerhan, J.R.;
- Stapleton, J.T.
Publication type:
Article
BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE).
Published in:
Hematological Oncology, 2017, v. 35, p. 213, doi. 10.1002/hon.2438_78
By:
- Thanarajasingam, G.;
- Dueck, A.C.;
- Novotny, P.J.;
- Witzig, T.E.;
- Habermann, T.M.;
- Nowakowski, G.S.;
- Flowers, C.R.;
- Bartlett, N.L.;
- Blum, K.A.;
- Pitcher, B.N.;
- Jung, S.;
- Atherton, P.J.;
- Tan, A.D.;
- Sloan, J.A.;
- Leonard, J.P.
Publication type:
Article
PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 419, doi. 10.1002/hon.2440_1
By:
- Jaeger, U.;
- Kalakonda, N.;
- Everaus, H.;
- Fustier, P.;
- Jaeger, J.;
- Manzke, O.;
- Nowakowski, G.S.
Publication type:
Article

Found: 16